Progress in the treatment of NK-cell lymphoma/leukemia

作     者：Ayumi Fujimoto Ritsuro Suzuki Ayumi Fujimoto;Ritsuro Suzuki

作者机构：Department of HematologyShimane University HospitalIzumoShimane 693-8501Japan 

出 版 物：《Journal of Cancer Metastasis and Treatment》 (癌症转移与治疗（英文版）)

年 卷 期：2021年第7卷第1期

页      面：901-914页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Extranodal NK/T-cell lymphoma nasal type aggressive NK-cell leukemia Epstein-Barr virus hematopoietic stem cell transplantation L-asparaginase 

摘      要：Natural killer(NK)/T cell lymphoma includes two major subtypes of disease,specifically extranodal NK/T cell lymphoma,nasal type(ENKL)and aggressive NK cell leukemia(ANKL).Both are strongly associated with Epstein Barr virus and are prevalent in East Asia and Latin America.Except for that of limited-stage ENKL,the prognosis of both diseases was poor in the previous decade.The advent of non-anthracycline-based chemoradiotherapy has contributed to an improvement in ENKL prognosis,but there is still room for further treatment progress.Recently,the high efficacy of PD-1 antibody was reported in relapsed or refractory ENKL patients.This was later supported by the finding that PD-L1/PD-L2 genetic alterations are frequently observed in ENKL and ANKL patients.Due to the rarity of the disease,a standard treatment for ANKL remains to be established.Currently,allogeneic stem cell transplantation is the only curative treatment,and this is even applicable to chemo-resistant ANKL patients.In this review,we focus on recent treatment approaches for NK/T cell lymphomas including novel agents.